SAN

79.89

+2.36%↑

SRT3

218.8

+4.89%↑

ORNBV.FI

68.5

+3.4%↑

SAN

79.89

+2.36%↑

SRT3

218.8

+4.89%↑

ORNBV.FI

68.5

+3.4%↑

SAN

79.89

+2.36%↑

SRT3

218.8

+4.89%↑

ORNBV.FI

68.5

+3.4%↑

SAN

79.89

+2.36%↑

SRT3

218.8

+4.89%↑

ORNBV.FI

68.5

+3.4%↑

SAN

79.89

+2.36%↑

SRT3

218.8

+4.89%↑

ORNBV.FI

68.5

+3.4%↑

Search

Carl Zeiss Meditec AG

Chiusa

SettoreSettore sanitario

26.46 5.42

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

25.06

Massimo

26.48

Metriche Chiave

By Trading Economics

Entrata

52M

80M

Vendite

-161M

467M

P/E

Media del settore

16.422

67.147

EPS

0.03

Rendimento da dividendi

2.09

Margine di Profitto

12.778

Dipendenti

5,784

EBITDA

124M

187M

Raccomandazioni

By TipRanks

Raccomandazioni

Neutrale

Previsioni per 12 mesi

+11.15% upside

Dividendi

By Dow Jones

Rendimento da dividendi

Media del settore

2.09%

2.36%

Utili prossimi

12 mag 2026

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

-1.2B

2.3B

Apertura precedente

21.04

Chiusura precedente

26.46

Notizie sul Sentiment di mercato

By Acuity

27%

73%

105 / 348 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Bullish Evidence

Carl Zeiss Meditec AG Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

29 apr 2026, 23:53 UTC

Utili

Naver Posts Weaker First-Quarter Earnings

29 apr 2026, 23:41 UTC

Azioni calde

Stocks to Watch: Meta Platforms, Alphabet, Qualcomm, Amazon.com

29 apr 2026, 23:55 UTC

Utili

Samsung Electronics 1Q Net Profit Beat FactSet-Compiled Consensus

29 apr 2026, 23:54 UTC

Utili

Samsung Electronics 1Q Net KRW47.225T Vs. Net KRW8.223T >005930.SE

29 apr 2026, 23:52 UTC

Utili

Samsung Electronics 1Q Oper Pft KRW57.233T Vs. Pft KRW6.685T >005930.SE

29 apr 2026, 23:51 UTC

Utili

Samsung Electronics 1Q Rev KRW133.873T Vs. KRW79.141T >005930.SE

29 apr 2026, 23:51 UTC

Discorsi di Mercato

Nikkei May Fall Amid Uncertainty Over Mideast Conflict -- Market Talk

29 apr 2026, 23:34 UTC

Discorsi di Mercato

Gold Edges Higher on Likely Technical Recovery -- Market Talk

29 apr 2026, 23:24 UTC

Utili

CSC Financial 1Q Results Supported By Higher Income From Fees, Commission>6066.HK

29 apr 2026, 23:24 UTC

Utili

CSC Financial Gains From Changes in Fair Value on Financial Assets Also Aided Results>6066.HK

29 apr 2026, 23:24 UTC

Utili

CSC Financial 1Q Net CNY3.67B Vs. Net CNY1.84B >6066.HK

29 apr 2026, 23:24 UTC

Utili

CSC Financial 1Q Rev CNY7.70B Vs. CNY4.74B >6066.HK

29 apr 2026, 23:22 UTC

Utili

China Longyuan 1Q Net CNY1.70B, Down 14%

29 apr 2026, 23:22 UTC

Utili

China Longyuan: Power Generation Down 2.9% as of End-March

29 apr 2026, 23:20 UTC

Utili

China Longyuan: 1Q Rev From Wind Power Fell, Rev From Solar Power Rose

29 apr 2026, 23:20 UTC

Utili

China Longyuan 1Q Rev CNY7.87B, Down 3.6%

29 apr 2026, 23:19 UTC

Utili

China Vanke 1Q Loss CNY5.95B Vs. Loss CNY6.25B >000002.SZ

29 apr 2026, 23:19 UTC

Utili

China Vanke: Weak China Real Estate Market Continue to Weigh on Results>000002.SZ

29 apr 2026, 23:19 UTC

Utili

China Vanke 1Q Rev CNY28.93B Vs. CNY37.99B >000002.SZ

29 apr 2026, 23:19 UTC

Utili

China Vanke 1Q Loss Narrows>000002.SZ

29 apr 2026, 23:18 UTC

Utili

Naver1Q Net Profit Missed FactSet-Compiled Consensus

29 apr 2026, 23:17 UTC

Utili

Naver 1Q Net KRW291.00B Vs. Net KRW423.70B >035420.SE

29 apr 2026, 23:15 UTC

Utili

Naver 1Q Oper Pft KRW541.80B Vs. Pft KRW505.30B >035420.SE

29 apr 2026, 23:15 UTC

Utili

Naver 1Q Rev KRW3.241T Vs. KRW2.787T >035420.SE

29 apr 2026, 23:13 UTC

Utili

CICC: Gains From Investments in Financial Instruments Also Aided Results >3908.HK

29 apr 2026, 23:12 UTC

Utili

CICC Results Supported by Increase in Fee, Commission Income >3908.HK

29 apr 2026, 23:11 UTC

Utili

CICC 1Q Rev CNY8.83B Vs. CNY5.72B >3908.HK

29 apr 2026, 23:11 UTC

Utili

CICC 1Q Net CNY3.58B Vs. Net CNY2.04B >3908.HK

29 apr 2026, 23:04 UTC

Utili

Microsoft Reports Strong Cloud Growth, but Questions About AI Returns Persist -- WSJ

29 apr 2026, 23:04 UTC

Utili

Meta Reports Big Revenue Jump and Projected Spending Increase -- 3rd Update

Confronto tra pari

Modifica del prezzo

Carl Zeiss Meditec AG Previsione

Obiettivo di Prezzo

By TipRanks

11.15% in crescita

Previsioni per 12 mesi

Media 28.61 EUR  11.15%

Alto 32 EUR

Basso 22.4 EUR

Basato su 9 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Carl Zeiss Meditec AG - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Neutrale

9 ratings

0

Acquista

8

Mantieni

1

Vendi

Punteggio Tecnico

By Trading Central

58.75 / 60.35Supporto e resistenza

A breve termine

Bullish Evidence

A termine intermedio

Strong Bullish Evidence

A lungo termine

Weak Bearish Evidence

Sentiment

By Acuity

105 / 348 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Prove rialziste

VolatilitĂ 

Sotto la media

Volume delle notizie (RCV)

Sopra la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Carl Zeiss Meditec AG

Carl Zeiss Meditec AG operates as a medical technology company in Germany, rest of Europe, North America, and Asia. It operates in two segments, Ophthalmology and Microsurgery. The Ophthalmology segment offers products and solutions for the diagnosis and treatment of chronic eye diseases, such as ametropia (refraction), cataracts, glaucoma, and renital disorders. This segment also provides devices for general ophthalmological examination and care, including slit lamps, refractometers, tonometers, optical coherence tomography devices, and fundus cameras; and devices for functional diagnostics (perimeters), as well as digital products for storage, evaluation, and sharing of clinical data. In addition, this segment offers surgical ophthalmology products comprising surgical microscopes, biometers, phacoemulsification, and vitrectomy devices; intraocular lenses for cataract patients; and systems and consumables for laser eye surgery. The Microsurgery segment provides products and solutions for invasive surgical treatments; and solutions in the area of ear, nose and throat, plastic and reconstructive, neuro, dental, and spinal surgeries. It serves physicians in various fields and hospitals. The company was founded in 1846 and is headquartered in Jena, Germany. Carl Zeiss Meditec AG is a subsidiary of Carl Zeiss AG.
help-icon Live chat